Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Societal Costs of Moderate-to-severe Atopic Dermatitis Occurring in Adulthood: A Danish Register-based Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Wearing Occlusive Gloves Increases the Density of Staphylococcus aureus in Patients with Hand Eczema

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  3. Characterization of the Oral and Gut Microbiota in Patients with Psoriatic Diseases: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Risk of Anogenital Warts in Renal Transplant Recipients Compared with Immunocompetent Controls: A Cross-sectional Clinical Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Topical Zinc Oxide Assessed in Two Human Wound-healing Models

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Identifying patient characteristics associated with achieving treatment response to biologics in patients with psoriasis could prevent expensive switching between biologics. The aim of this study was to identify patient characteristics that predict the efficacy of treatment for biologics that inhibit tumour necrosis factor-α, interleukin-12/-23, and -17A. The study investigated biologic-naïve patients from the DERMBIO registry treated with adalimumab, etanercept, infliximab, secukinumab, or ustekinumab. Multivariable logistic models were conducted to assess associations between patient characteristics and treatment response. A total of 2,384 patients were included (adalimumab n = 911; etanercept n = 327; infliximab n = 152; secukinumab n = 323; ustekinumab n = 671). Smoking (odds ratio 0.74; 95% confidence interval (CI) 0.56-0.97; p = 0.03) and higher bodyweight (odds ratio 0.989; 95% CI 0.984-0.994; p < 0.001) reduced the odds of achieving response defined as Psoriasis Area and Severity Index ≤2.0 after 6 months of treatment. In conclusion, higher bodyweight and smoking were associated with a reduced probability of treatment response for tumour necrosis factor-α inhibitors, ustekinumab, and secukinumab.

TidsskriftActa Dermato-Venereologica
Udgave nummer10
Sider (fra-til)adv00579
StatusUdgivet - 26 okt. 2021

ID: 69211337